ClinicalTrials.gg
Status unknownNCT03405675SLASUpdated Mar 14, 2019

Gerontology Research Programme: The Singapore Longitudinal Ageing Studies (SLAS I & II)

An observational study in Cognitive Changes Due to Organic Disorder (Finding), Dementia and Mild Cognitive Impairment, sponsored by National University of Singapore. Status unknown at 1 site in Singapore. Open to participants aged 55 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-14.

Sponsored by National University of Singapore · Observational

The sponsor has not verified this record recently (last verified Mar 2019), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6,183
Ages
55 Years and older
Sex
All
01

Study summary

The Gerontology Research Programme (GRP) in the National University Singapore's Department of Psychological Medicine, was formed to coordinate and facilitate the conduct of multi-disciplinary research on in a wide range of research on ageing and health. The establishment of the Singapore Longitudinal Aging Cohort will provide a large community-based cohort of elderly subjects for observational studies with useful clinical applications. Research synergy is achieved in terms of pooling multi-disciplinary expertise, and combining genetic, biological, environmental, behavioural, social, clinical, and health services approaches to gerontological research.

Read the detailed description

The SLAS is the principal longitudinal cohort study in GRP. The SLAS is a community-based longitudinal epidemiologic study that aims to increase the understanding of ageing and health, and the factors that influence the ageing process. SLAS seeks to identify the cognitive, biomedical, lifestyle and behavioral, as well as psychosocial risk and protective factors that affect the transition from healthy ageing to functional impairment, illness and death.

Participants recruited into SLAS are community-dwelling seniors, aged 55 and above, from various areas in Singapore. Participants are approached door-to-door, are provided detailed information regarding their participation, and are required to provide informed consent before enrollment into the study. The study procedure includes a baseline survey upon enrollment, and participants are revisited on a 3-yearly basis thereafter.

Enrolled subjects provide baseline data through structured interviews, physician assessments, laboratory testing, and self-reports of conditions, symptoms, and risk behaviors. Data in the study is collected by trained research staff and nurses. The information to be collected include:

Outcomes:

Primary Outcomes

4 Main Primary Outcomes

  1. Mild cognitive impairment and cognitive functioning
  2. Frailty
  3. Depression, anxiety (Mood disorder I)
  4. Successful and healthy ageing

Basic screening followed by diagnostic tests.

Cognitive domain functioning. Particpants are screened fro cogntve impairment using global cognitive tests (MMSE and MOCA). An exhaustive neuropsychological assessment battery is also conducted to assess specific cognitive domain functioning of participants. Selected participants that meet screening criteria, thus indicating the presence of possible cognitive impairment, undergo further testing to determine their cognitive functioning status (cognitively normal, mild cognitive impairment, cognitive decline, or dementia), as diagnosed by a panel of geriatricians, in accordance with the DSM-IV-TR criteria for dementia (1), and the MCI Working Group of the European Consortium on Alzheimer's disease criteria (2).

Frailty assessment. A battery of measures, including self-report, physical assessments and anthropometric measures, is administered to measure the frailty status of the individuals, in accordance with the Fried et al.'s phenotype criteria (3).

Psychiatric assessment. Several self-reported questionnaires are administered to measure the symptomatology of common psychiatric disorders such as depression, among others. Selected participants that meet screening criteria, thus indicating the presence of possible psychiatric disorders, would undergo further testing to determine their mental health state, in accordance with the DSM-IV-TR criteria (1).

Successful and healthy ageing. Successful and healthy ageing is determined by a number of self-reported and objective measurements of health which aim to reflect the overall and physical health, cognitive, emotional and social well-functioning (inclusive of life engagement and life satisfaction) of the individual.

Secondary Outcomes

Physical domain functioning. Self-reported measures as well as physical assessments would be conducted to measure physical functioning, disability and independence in activities of daily living among participants.

Health, health services utilization. Data regarding the history of chronic medical conditions and falls, medication use, use of hospital and primary care services and self-rated health.

Quality of Life. Self-reported measures would be conducted to measure the quality of life amongst the participants.

Mortality. The date of death of participants would be recorded, as well as assessing the Singapore National Registry of Diseases Office (NRDO).

Respiratory functioning. Data regarding respiratory functioning would be collected via a spirometry test.

Risk and protective factors:

Socioeconomic and demographic variables. Information regarding the age, gender, educational status and household income would be collected from the participants via self-report.

Medical history. Information regarding the history of selected medical and mental disorders would be collected from the participants via self-report.

Biological determinants. Biological specimens (blood and urine) will be analyzed for constituents of interest (e.g. micronutrients, lipid and glucose levels, among others).

Pharmacological determinants. The use of pharmacological agents such as anti-inflammatory, cholesterol-lowering and other drugs will be recorded via a self-report measure.

Nutrition. Participants would be assessed on their nutritional status and dietary consumption (NSI screening, MNA screening, food frequency, 2-day food diary). The dietary records are analyzed for nutrients of interest and phytochemicals such as B12, B6, folate, curcumin, and other nutritional supplements.

Lifestyle and health risk behaviors. Lifestyle behaviors measured would include physical, leisure and social activities engagement duration and frequency. Health risk behaviors measured include the body mass index and other anthropometric measures, smoking, customary physical activity, social and productive activities and alcohol use among participants.

Psycho-social data. Self-reported questionnaires are administered to measure life satisfaction, personality, religiosity, social support and asocial network connections for select participants.

02

Conditions studied

  • Cognitive Changes Due to Organic Disorder (Finding)
  • Dementia
  • Mild Cognitive Impairment
  • Frailty
  • Depression
  • Healthy Ageing
  • Biological Ageing

Keywords

  • Dementia
  • Mild cognitive impairment
  • Cognitive abilities and changes
  • Functional change and disabilities
  • Depression
  • Health and social services utilization
  • Quality of life
  • Adverse drug effects
  • Social network and support
  • Self-rated health
  • Medical morbidities
  • Falls
  • Health risk behaviors
  • Nutrition
  • Apo-E lipoprotein
  • Phytochemicals
  • B12
  • Folate
  • Homocysteine
  • Lifestyle
  • Physical activity
  • Leisure activity
  • Successful ageing
  • Mortality
03

In context

Signs and Symptoms

221 studies on the registry are indexed under Signs and Symptoms; 22 are open to participants now.

This study's enrollment of 6,183 is above the median of 189 across 58 observational studies indexed under Signs and Symptoms.

Browse Signs and Symptoms studies →

Lead sponsor

National University of Singapore is the lead sponsor of 212 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Community-dwelling Elderly (>55 years old) that are able to self-ambulate and who possess sufficient cognitive capacity for participation. Individuals with severe physical or mental disabilities were excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to self-ambulate
  • Adequate cognitive capacity for participation

Exclusion criteria

Exclusion Criteria:

  • Individuals with severe physical or mental disabilities were excluded.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6,183 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • SLAS 1

    The subjects (N=2800) are recruited from all residents aged 55 years and above in Singapore in the areas covered by the South-East Community Development Council: Geylang, Aljunied, MacPherson, Marine Parade and Bedok (SLAS-I).

    Other: SLAS 1

  • SLAS 2

    An additional 3200 subjects are recruited from residents in the Bukit Merah and Jurong (SLAS-II).

    Other: SLAS 2

Interventions

  • OtherSLAS 1

    NA. Observational study, no interventions administered.

  • OtherSLAS 2

    NA. Observational study, no interventions administered.

06

What researchers measure

Primary outcomes

  1. Dementia and Mild Cognitive Impairment (MCI) Subtyping (Clinical diagnosis of different stages of Dementia)

    Dementia and MCI is determined by clinical case conference adjudication where geriatric and psychiatric clinicians convene to determine the diagnosis of a case, utilizing the data from (i) Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) (4-5); (ii) Clinical Dementia rating scale: a 5-point scale used to characterize 6 cognitive and functional domain performance: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, and Personal Care (6). Information to make each rating is obtained through a semi-structured interview of the patient and a reliable informant (e.g. family member). A higher score indicates increased severity of cognitive impairment; (iii) Informant Questionnaire of Cognitive Decline in the Elderly (IQCODE) - reliable informants report on the cognitive state of the participant (7); (iv) a scale on self-reported subjective cognitive difficulties; and (v) a neuropsychological assessment battery (described below).

    Time frame: 20 years - once every 3-4 years

  2. Global and specific domain cognitive functioning ability (Measuring of Global and Specific domain of Cognitive functions)

    MMSE (4) and MoCA (5) - 30 items, total scores range from 0-30, higher scores indicate better cognitive functioning. A cut-off of a score of =\<25 is determined as screening positive for cognitive impairment. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (8) - measures immediate memory, visuospatial ability, language, attention, delayed memory, and a global cognitive functioning score (a summation of domain scores). A neurocognitive battery measures immediate and delayed memory/learning, visuospatial ability, language, attention, and executive functioning. All domains are calculated by weighted averages of age and education adjusted scores. Tests: (i) Digit Span forward and backwards tasks (9); (ii) Rey's Auditory Verbal Learning Test (10); (iii) Story Memory Test (11); (iv) Brief Visuospatial Memory Test - Revised (12); (v) Boston Naming Test (13); (vi) Clock Reading Test; (viii) Colour Trials 1 and 2 (14); (ix) Block Design task (9).

    Time frame: 20 years - once every 3-4 years

  3. Frailty (Measuring the physical and Cognitive Frailty)

    Physical frailty was assessed by scores (1 = present, 0 = absent) for five components (shrinking, weakness, slowness, exhaustion, and low Physical Activity (PA)) proposed by Fried et al (3), with the following operational modifications: (i) Shrinking was defined by unintentional weight loss of 4 kg or more in the past 6 months, or BMI less than 18.5 kg/m2, or calf circumference of 31 cm or less. (ii) Weakness was assessed by knee extension strength task in kilogram. (iii) Slowness was assessed by a gait speed test (15). (iv) Exhaustion was measured as a summed score of 3 questions (1-5), "Did you have lots of energy/feel tired (reverse-scored, rs)/worn out (rs)?" (16). A score of \<10 was used to denote exhaustion. (v) Low PA was measured by the LASA PA scale, with those falling below the local gender-specific lowest quintile deemed as low PA (17). Participants are categorised by their total scores as robust (score = 0), pre-frail (score = 1-2), and frail (score = 3-5).

    Time frame: 20 years - once every 3-4 years

  4. Depressive symptoms and diagnosis (Measuring of Depressive symptoms and assessment of stages of Depression)

    Depressive symptoms are assessed by the 15-item version of the Geriatric Depression Scale (GDS), with a higher score indicating higher depressivity (18). A cut-off score of 5 is used as indicating the presence of depression. Additionally, participants are formally diagnosed by a medically trained research fellow for common mood-related psychiatric conditions using the Structured Clinical Interview for DSM Disorders (SCID) of DSM IV-TR (1), such as Major Depressive Disorder, Minor Depression, Dysthmic Disorder, Mania/Hypomania disorder, Anxiety and panic disorder, Obsessive-compulsive disorder, Post traumatic stress disorder, Psychotic disorder, Mood disorder due to a General Medical Condition and Alcohol abuse disorders, if they screen as positive for depression on the GDS.

    Time frame: 20 years - once every 3-4 years

  5. Successful ageing (Measuring the biological, psycho-social and lifestyle factors associated with Successful Ageing)

    Successful aging is previously defined (25). Briefly, a score of successful ageing reflects the overall and physical health, cognitive, emotional, social well-functioning, including life engagement \& satisfaction. Physical health and functional well-being was defined as a "good/excellent" self-reported health and IADL independence (20). Cognitive well-functioning and emotional wellbeing was denoted by a minimum MMSE score of 26 (4), and a score below 5 on the GDS (≤5) (18). Social functioning and active engagement in life activities was assessed using a validated questionnaire (26) on participation levels in social, recreational, civic activities, voluntary work, employment/business, and domestic activities. Overall positive life satisfaction was determined using the Life Satisfaction Scale that assessed interest in life, happiness, loneliness, and general ease of living (27). Total summed score ranges from 4 to 18, with the lowest decile indicating a positive life satisfaction.

    Time frame: 20 years - once every 3-4 years

Secondary outcomes

  1. Self-reported independent functioning (Measuring the BADL and IADL)

    Self-reported Independent Functioning is assessed using the Barthel Index (19) and the Lawton and Brody Instrumental Activity of Daily Living Inventory (20), whereby participants report the degree of dependence on others for several daily and instrumental tasks.

    Time frame: 20 years - once every 3-4 years

  2. Physical performance (Measuring the physical performance tests)

    Assessed by the Physical Performance Battery which includes the Performance-Oriented Mobility Assessment-Balance and Gait scales (21-22), with a higher score indicating a higher performance in terms of balance or gait; as well as the amount of force displaced in Newtons on a handgrip and knee extension dynamometer. The scores for each of the tests would be combined into a weighted average that reflects overall physical performance.

    Time frame: 20 years - once every 3-4 years

  3. Health services utilization (Measuring cost and frequency of health services utilization)

    Self-reported frequency of doctor visits over a past 12-month period.

    Time frame: 20 years - once every 3-4 years

  4. Quality of life (Measuring the Quality of life SF 12)

    Assessed by self-reported scales: (i) EQ5D- 3L - a measure of health-related quality of life that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale (23). (ii) 12-Item Short Form Survey (SF-12) is a 12-item questionnaire used to assess generic health outcomes from the patient's perspective, covering the eight domains of health outcomes: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional \& mental health (24).

    Time frame: 20 years - once every 3-4 years

  5. Mortality (Measuring the risk factors related to mortality)

    Date and cause of death data is collected by computerized record linkage with the National Death Registry through the Singapore National Registry of Diseases Office (NRDO).

    Time frame: 20 years

  6. Post-bronchodilation spirometry (Measuring the lung functions tests)

    A measurement of lung function which yields the (i) Forced vital capacity - the determination of the vital capacity from a maximally forced expiratory effort; (ii) the FEV1 - volume that has been exhaled at the end of the first second of forced expiration; and the (iii) Peak expiratory flow: The highest forced expiratory flow measured with a peak flow meter. Measurements are made following American Thoracic Society (ATS) criteria for spirometric standardization and procedures, based on the best of four readings, with less than 5% variation in the two best readings. FEV1 is expressed as the percentage of predicted from local norms.

    Time frame: 20 years - once every 3-4 years

07

Study locations

1 site
  • National University of Singapore
    Singapore, 119260, Singapore
08

References and documents

Publications

  • American Psychiatric Association. Diagnostic and statistical manual of Mental Disorders, (4th ed., text rev.; DSM-IV-TR). American Psychiatric Association, Washington. 2000.
  • Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili F, Scheltens P, Vellas B, Touchon J; MCI Working Group of the European Consortium on Alzheimer's Disease (EADC). Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):714-8. doi: 10.1136/jnnp.2005.085332. Epub 2006 Mar 20. PubMed 16549412 ↗
  • Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56. doi: 10.1093/gerona/56.3.m146. PubMed 11253156 ↗
  • Folstein MF, Folstein SE, McHugh PR, Fanjiang G. Mini-Mental State Examination: MMSE user's guide. Psychology Assessment Resources; 2000.
  • Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. Erratum In: J Am Geriatr Soc. 2019 Sep;67(9):1991. doi: 10.1111/jgs.15925. PubMed 15817019 ↗
  • O'Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, Lupo PJ, Reisch JS, Doody R; Texas Alzheimer's Research Consortium. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol. 2008 Aug;65(8):1091-5. doi: 10.1001/archneur.65.8.1091. PubMed 18695059 ↗
  • Jorm AF. A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. Psychol Med. 1994 Feb;24(1):145-53. doi: 10.1017/s003329170002691x. Erratum In: Psychol Med 1995 Mar;25(2):437. PubMed 8208879 ↗
  • Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998 Jun;20(3):310-9. doi: 10.1076/jcen.20.3.310.823. PubMed 9845158 ↗
  • Wechsler D. Wechsler adult intelligence scale-fourth. San Antonio, TX: The Psychological Corporation Google Scholar; 2008.
  • Rey A. L'examen psychologique dans les cas d'encéphalopathie traumatique.(Les problems.). Archives de psychologie (1941).
  • Yeo D, Gabriel C, Chen C, Lee S, Loenneker T, Wong M. Pilot validation of a customized neuropsychological battery in elderly Singaporeans. Neurol J South East Asia 1997 2(123).
  • Benedict RHB. Brief visuospatial memory test - revised: Professional manual. Lutz, FL: Psychological Assessment Resources, Inc; 1997.
  • Kaplan E, Goodglass H, Weintraub S. Boston naming test. Pro-ed; 2001.
  • D'Elia LF, Satz P, Uchiyama CL, White T. Color Trails Test: Professional Manual. Odessa (Florida): Psychological Assessment Resources; 1996.
  • Kluger A, Gianutsos JG, Golomb J, Wagner A Jr, Wagner D, Scheurich S. Clinical features of MCI: motor changes. Int Psychogeriatr. 2008 Feb;20(1):32-9. doi: 10.1017/S1041610207006461. PubMed 18072982 ↗
  • Ware JE, Keller SD, Kosinski M. SF-12: How to Score the SF-12 Physical and Mental Health Summary Scales. Lincoln, RI: QualityMetric; 1998.
  • Siebeling L, Wiebers S, Beem L, Puhan MA, Ter Riet G. Validity and reproducibility of a physical activity questionnaire for older adults: questionnaire versus accelerometer for assessing physical activity in older adults. Clin Epidemiol. 2012;4:171-80. doi: 10.2147/CLEP.S30848. Epub 2012 Jul 16. PubMed 22866018 ↗
  • Vinkers DJ, Gussekloo J, Stek ML, Westendorp RG, Van Der Mast RC. The 15-item Geriatric Depression Scale (GDS-15) detects changes in depressive symptoms after a major negative life event. The Leiden 85-plus Study. Int J Geriatr Psychiatry. 2004 Jan;19(1):80-4. doi: 10.1002/gps.1043. PubMed 14716703 ↗
  • MAHONEY FI, BARTHEL DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md State Med J. 1965 Feb;14:61-5. No abstract available. PubMed 14258950 ↗
  • Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969 Autumn;9(3):179-86. No abstract available. PubMed 5349366 ↗
  • Tinetti ME, Williams TF, Mayewski R. Fall risk index for elderly patients based on number of chronic disabilities. Am J Med. 1986 Mar;80(3):429-34. doi: 10.1016/0002-9343(86)90717-5. PubMed 3953620 ↗
  • Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc. 1986 Feb;34(2):119-26. doi: 10.1111/j.1532-5415.1986.tb05480.x. No abstract available. PubMed 3944402 ↗
  • Rabin R, Oemar M, Oppe M, Janssen B, Herdman M. EQ-5D-3L User Guide: Basic information on how to use the EQ-5D-3L instrument. Rotterdam: EuroQol Group; 2011.
  • Ware JE, Kolinski M, Keller SD. How to Score the SF-12 Physical and Mental Health Summaries: A User's Manual. Boston: The Health Institute, New England Medical Centre, Boston, MA; 1995.
  • Ng TP, Broekman BF, Niti M, Gwee X, Kua EH. Determinants of successful aging using a multidimensional definition among Chinese elderly in Singapore. Am J Geriatr Psychiatry. 2009 May;17(5):407-16. doi: 10.1097/JGP.0b013e31819a808e. PubMed 19390298 ↗
  • Niti M, Yap KB, Kua EH, Tan CH, Ng TP. Physical, social and productive leisure activities, cognitive decline and interaction with APOE-epsilon 4 genotype in Chinese older adults. Int Psychogeriatr. 2008 Apr;20(2):237-51. doi: 10.1017/S1041610207006655. Epub 2008 Jan 11. PubMed 18190728 ↗
  • Koivumaa-Honkanen H, Honkanen R, Viinamaki H, Heikkila K, Kaprio J, Koskenvuo M. Self-reported life satisfaction and 20-year mortality in healthy Finnish adults. Am J Epidemiol. 2000 Nov 15;152(10):983-91. doi: 10.1093/aje/152.10.983. PubMed 11092440 ↗
  • Ng TP, Lee TS, Lim WS, Chong MS, Yap P, Cheong CY, Rawtaer I, Liew TM, Gwee X, Gao Q, Yap KB. Functional mobility decline and incident mild cognitive impairment and early dementia in community-dwelling older adults: the Singapore Longitudinal Ageing Study. Age Ageing. 2022 Sep 2;51(9):afac182. doi: 10.1093/ageing/afac182. PubMed 36074716 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2003 (actual). Primary completion is estimated for Dec 2020, 209 months after the start.

Of 20 observational studies under Signs and Symptoms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 20. This study's planned 209 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Jan 23, 2018
StartActual
Jul 1, 2003
Primary completionEst.
Dec 31, 2020
CompletionEst.
Dec 31, 2020
Last update
Mar 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03405675
Collaborators
Karolinska Institutet, Tan Tock Seng Hospital, Ng Teng Fong General Hospital, St Luke's Hospital, Singapore, St. Paul's Hospital, Canada, Singapore Institute of Technology, Duke-NUS Graduate Medical School, Melbourne Health, University of California, University Hospital, Basel, Switzerland, Université de Sherbrooke, University Hospital Tuebingen, National University Hospital, Singapore, Khoo Teck Puat Hospital, Shanghai Jiao Tong University School of Medicine, University of British Columbia
Responsible party
A/Prof Ng Tze Pin (Associate Professorial Fellow and Research Director, National University of Singapore) — Principal investigator
First posted
Jan 23, 2018
Start date
Jul 1, 2003
Primary completion
Dec 31, 2020 (estimated)
Completion
Dec 31, 2020 (estimated)
Last update
Mar 14, 2019

Study contacts

Tze Pin Ng, PhD
principal investigator · National University of Singapore

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion